Beyond market trends, investors keen on maximizing returns delve into the world of stock picking. The right selections can be instrumental in catapulting your wealth.
The price of Viridian Therapeutics Inc (NASDAQ: VRDN) closed at $31.72 in the last session, up 0.99% from day before closing price of $31.41. In other words, the price has increased by $0.99 from its previous closing price. On the day, 1.71 million shares were traded. VRDN stock price reached its highest trading level at $32.015 during the session, while it also had its lowest trading level at $31.11.
Ratios:
We take a closer look at VRDN’s different ratios to gain a better understanding of the stock. For the most recent quarter (mrq), Quick Ratio is recorded 11.28 and its Current Ratio is at 11.28. In the meantime, Its Debt-to-Equity ratio is 0.05 whereas as Long-Term Debt/Eq ratio is at 0.05.
Wells Fargo Downgraded its Overweight to Equal Weight on December 19, 2024, whereas the target price for the stock was revised from $37 to $27.
Insider Transactions:
An investor can also benefit from insider trades by learning what management is thinking about the future direction of stock prices. A recent insider transaction in this stock occurred on Oct 23 ’25 when Fairmount Funds Management LLC bought 454,545 shares for $22.00 per share. The transaction valued at 9,999,990 led to the insider holds 3,914,458 shares of the business.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, VRDN now has a Market Capitalization of 3027420416 and an Enterprise Value of 2749606400. For the stock, the TTM Price-to-Sale (P/S) ratio is 42.77 while its Price-to-Book (P/B) ratio in mrq is 8.30. Its current Enterprise Value per Revenue stands at 38.842 whereas that against EBITDA is -8.392.
Stock Price History:
The Beta on a monthly basis for VRDN is 0.88, which has changed by 0.47192574 over the last 52 weeks, in comparison to a change of 0.12934029 over the same period for the S&P500. Over the past 52 weeks, VRDN has reached a high of $32.54, while it has fallen to a 52-week low of $9.90. The 50-Day Moving Average of the stock is 32.09%, while the 200-Day Moving Average is calculated to be 79.65%.
Shares Statistics:
According to the various share statistics, VRDN traded on average about 1.31M shares per day over the past 3-months and 2041760 shares per day over the past 10 days. A total of 95.44M shares are outstanding, with a floating share count of 85.96M. Insiders hold about 9.93% of the company’s shares, while institutions hold 89.95% stake in the company. Shares short for VRDN as of 1763078400 were 9472517 with a Short Ratio of 7.20, compared to 1760486400 on 9986922. Therefore, it implies a Short% of Shares Outstanding of 9472517 and a Short% of Float of 10.299999999999999.
Earnings Estimates
At present, 9.0 analysts are actively evaluating the performance of Viridian Therapeutics Inc (VRDN) in the stock market.The consensus estimate for the next quarter is -$1.13, with high estimates of -$1.02 and low estimates of -$1.26.
Analysts are recommending an EPS of between -$2.88 and -$4.71 for the fiscal current year, implying an average EPS of -$3.53. EPS for the following year is -$3.51, with 10.0 analysts recommending between -$2.33 and -$4.73.
Revenue Estimates
A total of 13 analysts have provided revenue estimates for VRDN’s current fiscal year. The highest revenue estimate was $125.79M, while the lowest revenue estimate was $70.7M, resulting in an average revenue estimate of $87.74M. In the same quarter a year ago, actual revenue was $302kBased on 14 analysts’ estimates, the company’s revenue will be $89.01M in the next fiscal year. The high estimate is $215.97M and the low estimate is $2.5M.
